keyword
MENU ▼
Read by QxMD icon Read
search

Onabotulinumtoxina

keyword
https://www.readbyqxmd.com/read/28919457/patterns-of-botulinum-toxin-treatment-for-spasticity-and-bleeding-complications-in-patients-with-thrombotic-risk
#1
Chetan P Phadke, Vivekanand Thanikachalam, Farooq Ismail, Chris Boulias
The purpose of this study was to assess the prevalence of compartment syndrome or major bleeding episodes and compare compartment syndrome, patient and intervention characteristics in 110 patients with stroke (treated with Warfarin, new oral anticoagulants, antiplatelet, or no anticoagulants) treated for spasticity in deep leg compartment muscles with botulinum toxin injections [onabotulinumtoxinA (n = 77); incobotulinumtoxinA (n = 33)]. We reviewed 674 injection cycles (range 1-25 cycles per patient) and found no cases of compartment syndrome in any patient groups...
September 15, 2017: Toxicon: Official Journal of the International Society on Toxinology
https://www.readbyqxmd.com/read/28905793/re-reduction-of-urgency-severity-is-the-most-important-factor-in-the-subjective-therapeutic-outcome-of-intravesical-onabotulinumtoxina-injection-for-overactive-bladder
#2
https://www.readbyqxmd.com/read/28879545/real-life-use-of-onabotulinumtoxina-for-symptom-relief-in-patients-with-chronic-migraine-repose-study-methodology-and-baseline-data
#3
Brendan Davies, Charly Gaul, Paolo Martelletti, Juan Carlos García-Moncó, Stephanie Brown
BACKGROUND: Migraine is a debilitating neurological disorder that affects 14.1% of the US and 14.7% of the European populations. Chronic migraine (CM) is broadly defined as headache occurring on ≥15 days per month for ≥3 months, and has an estimated worldwide prevalence of 1.4% to 2.2%. OnabotulinumtoxinA is currently approved for the treatment of CM in most European countries, and is the only preventative treatment approved for adults with CM, based on results from the PREEMPT clinical trial programme...
September 6, 2017: Journal of Headache and Pain
https://www.readbyqxmd.com/read/28877510/heart-rate-variability-modifications-induced-by-high-doses-of-incobotulinumtoxina-and-onabotulinumtoxina-in-hemiplegic-chronic-stroke-patients-a-single-blind-randomized-controlled-crossover-pilot-study
#4
Alessio Baricich, Elisa Grana, Stefano Carda, Andrea Santamato, Claudio Molinari, Carlo Cisari, Marco Invernizzi
BACKGROUND: Botulinum toxin type A is a valid and safe treatment for focal spasticity, with documented effects on both sympathetic and parasympathetic systems. Heart rate variability can provide detailed information about the control of the autonomic nervous system on cardiovascular activities. Previous studies in literature showed no significant changes in Heart Rate Variability with doses >600 U of incobotulinumtoxinA in chronic post stroke spastic patients; however, at present time, these results have not been confirmed with doses >600 U of onabotulinumtoxinA...
September 4, 2017: Toxicon: Official Journal of the International Society on Toxinology
https://www.readbyqxmd.com/read/28877509/botulinum-toxin-for-chronic-migraine-clinical-trials-and-technical-aspects
#5
Cristina Tassorelli, Grazia Sances, Micol Avenali, Roberto De Icco, Daniele Martinelli, Vito Bitetto, Giuseppe Nappi, Giorgio Sandrini
OnabotulinumtoxinA has been approved for the prophylaxis of chronic migraine following the demonstration of efficacy in two large controlled trials. Data collected from pragmatic studies in the real-life setting have contributed important additional information that are extremely useful for the management of this group of extremely disabled and challenging patients. The main findings from these studies are presented and discussed.
September 3, 2017: Toxicon: Official Journal of the International Society on Toxinology
https://www.readbyqxmd.com/read/28877353/adolescence-transitional-care-in-neurogenic-detrusor-overactivity-and-the-use-of-onabotulinumtoxina-a-clinical-algorithm-from-an-italian-consensus-statement
#6
REVIEW
Giovanni Palleschi, Giovanni Mosiello, Valerio Iacovelli, Stefania Musco, Giulio Del Popolo, Antonella Giannantoni, Antonio Carbone, Roberto Carone, Andrea Tubaro, Mario De Gennaro, Antonio Marte, Enrico Finazzi Agrò
AIMS: OnabotulinumtoxinA (onaBNTa) for treating neurogenic detrusor overactivity (NDO) is widely used after its regulatory approval in adults. Although the administration of onaBNTa is still considered off-label in children, data have already been reported on its efficacy and safety. Nowadays, there is a lack of standardized protocols for treatment of NDO with onaBNTa in adolescent patients in their transition from the childhood to the adult age. With the aim to address this issue a consensus panel was obtained...
September 6, 2017: Neurourology and Urodynamics
https://www.readbyqxmd.com/read/28808924/a-critical-evaluation-on-moh-current-treatments
#7
REVIEW
Andrea Negro, Martina Curto, Luana Lionetto, Simona Guerzoni, Luigi Alberto Pini, Paolo Martelletti
Migraine is the most frequent neurological disorder observed in clinical practice characterized by moderate to severe pain attacks associated with neurological, gastrointestinal, and dysautonomic symptoms. Each year, 2.5% of patients with episodic migraine develop chronic migraine (CM). CM is characterized by high frequency of the attacks that may result into chronic intake of abortive medications. Nearly, the 70% of CM patients referring to tertiary head centers show acute pain medications overuse that may lead to the development of medication overuse headache (MOH)...
August 15, 2017: Current Treatment Options in Neurology
https://www.readbyqxmd.com/read/28808734/what-is-the-true-catheterization-rate-after-intravesical-onabotulinumtoxina-injection
#8
Devin N Patel, Juzar Jamnagerwalla, Justin Houman, Jennifer T Anger, Karyn S Eilber
INTRODUCTION AND HYPOTHESIS: A known side effect of intravesical onabotulinumtoxinA (Botox®) injection for overactive bladder (OAB) is urinary retention requiring clean intermittent catheterization (CIC), the fear of which deters patients from choosing this therapy. In clinical practice, patients with an elevated postvoid residual (PVR) are often managed by observation only, providing they do not have subjective complaints or contraindications. We sought to determine the true rate of urinary retention requiring CIC in clinical practice...
August 14, 2017: International Urogynecology Journal
https://www.readbyqxmd.com/read/28808621/von-brunn-s-nests-and-follicular-cystitis-following-intradetrusor-onabotulinumtoxina-injections-for-overactive-bladder
#9
Silpa Nekkanti, Andrew Doering, Debra L Zynger, Andrew F Hundley
A 67-year-old female with refractory OAB was treated with intradetrusor Botox. She subsequently developed multiple papillary bladder lesions with tissue biopsy showing Von Brunn's nests. Von Brunn's nests are benign bladder lesions similar in appearance to a rare urothelial tumor called Nested Variant of Urothelial Carcinoma (NVUC). It is critical that patients with these findings undergo evaluation to rule out the presence of carcinoma. This finding suggests the possibility of a previously unreported adverse reaction in association with intradetrusor Botox...
September 2017: Urology Case Reports
https://www.readbyqxmd.com/read/28805473/the-impact-of-persistence-with-mirabegron-usage-vs-switching-to-onabotulinumtoxina-on-healthcare-costs-and-resource-utilization-in-patients-with-overactive-bladder-in-the-united-states
#10
Daniel Bin Ng, Robert Espinosa, Scott J Johnson, David Walker, Katherine Gooch
AIMS: To compare healthcare costs and resource utilization in patients with overactive bladder (OAB) in the US who switch from mirabegron to onabotulinumtoxinA (onabotA) with those who persist on mirabegron. MATERIALS AND METHODS: A retrospective observational claims analysis of the OptumHealth Administrative Claims database conducted between April 1, 2012 and September 30, 2015 used medical and pharmacy claims to identify patients with at least one OAB diagnosis who switched from mirabegron to onabotA (onabotA group) or persisted on mirabegron for at least 180 days (mirabegron persisters)...
September 4, 2017: Journal of Medical Economics
https://www.readbyqxmd.com/read/28805237/adult-spasticity-international-registry-study-methodology-and-baseline-patient-healthcare-provider-and-caregiver-characteristics
#11
Gerard E Francisco, Daniel S Bandari, Ganesh Bavikatte, Wolfgang H Jost, Aubrey Manack Adams, Joan Largent, Alberto Esquenazi
OBJECTIVE: The main aim of this study was to determine the utilization patterns and effectiveness of onabotulinumtoxinA (Botox®) for treatment of spasticity in clinical practice. DESIGN: An international, multicentre, prospective, observational study at selected sites in North America, Europe, and Asia. PATIENTS: Adult patients with newly diagnosed or established focal spasticity, including those who had previously received treatment with onabotulinum-toxin A...
August 31, 2017: Journal of Rehabilitation Medicine
https://www.readbyqxmd.com/read/28791229/impact-of-bladder-dysfunction-in-the-management-of-post-radical-prostatectomy-stress-urinary-incontinence-a-review
#12
REVIEW
Derek B Hennessey, Nathan Hoag, Johan Gani
Bladder dysfunction is a relatively common urodynamic finding post radical prostatectomy (RP). It can be the sole cause of post prostatectomy incontinence (PPI) or may be found in association with stress urinary incontinence (SUI). The aim of this review is to provide a comprehensive review of the diagnosis and different treatments of post RP bladder dysfunction. A comprehensive literature review using medical search engines was performed. The search included a combination of the following terms, PPI, detrusor overactivity (DO), detrusor underactivity (DU), impaired compliance, anticholinergic, onabotulinumtoxinA (Botox(®)) and sacral neuromodulation (SNM)...
July 2017: Translational Andrology and Urology
https://www.readbyqxmd.com/read/28789780/botulinum-toxin-in-parkinson-disease-tremor-a%C3%A2-randomized-double-blind-placebo-controlled-study-with-a-customized-injection-approach
#13
RANDOMIZED CONTROLLED TRIAL
Shivam Om Mittal, Duarte Machado, Diana Richardson, Divyanshu Dubey, Bahman Jabbari
BACKGROUND: In essential tremor and Parkinson disease (PD) tremor, administration of onabotulinumtoxinA via a fixed injection approach improves the tremor, but many patients (30%-70%) develop moderate to severe hand weakness, limiting the use of onabotulinumtoxinA in clinical practice. OBJECTIVE: To evaluate the safety and efficacy of incobotulinumtoxinA (IncoA) injection for the treatment of tremor in PD. PATIENTS AND METHODS: In this double-blind, placebo-controlled, crossover trial, 30 patients each received 7 to 12 (mean, 9) IncoA injections into hand and forearm muscles using a customized approach...
September 2017: Mayo Clinic Proceedings
https://www.readbyqxmd.com/read/28771936/intradetrusor-onabotulinumtoxina-injections-for-refractory-neurogenic-detrusor-overactivity-incontinence-do-we-need-urodynamic-investigation-for-outcome-assessment
#14
Miriam Koschorke, Lorenz Leitner, Helen Sadri, Stephanie C Knüpfer, Ulrich Mehnert, Thomas M Kessler
OBJECTIVE: To evaluate if urinary continence after intradetrusor onabotulinumtoxinA injections is sufficient for appropriate outcome assessment or if urodynamic investigation (UDI) is needed. PATIENTS AND METHODS: A consecutive series of 148 patients undergoing intradetrusor onabotulinumtoxinA injections for refractory neurogenic detrusor overactivity (NDO) incontinence were prospectively evaluated. Patients underwent UDI prior and 6 weeks after onabotulinumtoxinA injections...
August 3, 2017: BJU International
https://www.readbyqxmd.com/read/28766236/the-impact-of-onabotulinumtoxina-on-severe-headache-days-preempt-56-week-pooled-analysis
#15
Manjit Matharu, Rashmi Halker, Patricia Pozo-Rosich, Ronald DeGryse, Aubrey Manack Adams, Sheena K Aurora
BACKGROUND: OnabotulinumtoxinA has been shown to reduce headache-days among patients with chronic migraine (CM). The objective of this analysis was to determine whether onabotulinumtoxinA has an impact on headache-day severity in patients with CM among those patients who were deemed non-responders based on reduction in the frequency of headache days alone. METHODS: Data from the Phase 3 REsearch Evaluating Migraine Prophylaxis Therapy (PREEMPT) clinical trial program (a 24-week, 2-treatment cycle, double-blind, randomized, placebo-controlled, parallel-group phase, followed by a 32-week, 3-treatment cycle, open-label phase) were pooled for analysis...
December 2017: Journal of Headache and Pain
https://www.readbyqxmd.com/read/28758415/utilization-and-safety-of-onabotulinumtoxina-for-the-prophylactic-treatment-of-chronic-migraine-from-an-observational-study-in-europe
#16
Manjit Matharu, Julio Pascual, Ingela Nilsson Remahl, Andreas Straube, Arlene Lum, Gudarz Davar, Dawn Odom, Lee Bennett, Christina Proctor, Lia Gutierrez, Elizabeth Andrews, Catherine Johannes
Objective To examine treatment utilization patterns and safety of onabotulinumtoxinA for the prophylactic treatment of chronic migraine in routine clinical practice. Background Clinical trials support onabotulinumtoxinA for the prophylaxis of headache in patients with chronic migraine, but real-world data are limited. Design/methods A prospective, observational, post-authorization study in adult patients with chronic migraine treated with onabotulinumtoxinA. Data were collected at the first study injection and approximately every three months for ≤52 weeks for utilization and ≤64 weeks for safety data, and summarized using descriptive statistics...
January 1, 2017: Cephalalgia: An International Journal of Headache
https://www.readbyqxmd.com/read/28752512/medical-treatment-guidelines-for-preventive-treatment-of-migraine
#17
Tzu-Chou Huang, Tzu-Hsien Lai, Treatment Guideline Subcommittee Of Taiwan Headache Society Taiwan Headache Society
The Treatment Guideline Subcommittee of the Taiwan Headache Society evaluated the medications currently used for migraine prevention in Taiwan. We assessed the results of new published drug trials, information from medical database and referred to the latest guidelines published. After comprehensive discussion, we proposed Taiwanese consensus about the preventive treatment for migraine including recommendation levels, strength of evidences, and related prescription information regarding dosage and adverse effects...
March 15, 2017: Acta Neurologica Taiwanica
https://www.readbyqxmd.com/read/28751016/sacral-neuromodulation-is-preferred-over-onabotulinumtoxina-injection-for-overactive-bladder-in-women-con
#18
Gregory T Bales
No abstract text is available yet for this article.
September 2017: Journal of Urology
https://www.readbyqxmd.com/read/28751015/sacral-neuromodulation-is-preferred-over-onabotulinumtoxina-injection-for-overactive-bladder-in-women-pro
#19
Stephen R Kraus
No abstract text is available yet for this article.
September 2017: Journal of Urology
https://www.readbyqxmd.com/read/28750504/does-myofascial-and-trigger-point-treatment-reduce-pain-and-analgesic-intake-in-patients-undergoing-onabotulinumtoxina-injection-due-to-chronic-intractable-migraine-a-pilot-single-blind-randomized-controlled-trial
#20
Marialuisa Gandolfi, Christian Geroin, Nicola Valè, Fabio Marchioretto, Andrea Turrina, Eleonora Dimitrova, Stefano Tamburin, Anna Serina, Paola Castellazzi, Andrea Meschieri, François Ricard, Leopold Saltuari, Alessandro Picelli, Nicola Smania
BACKGROUND: Chronic migraine is a disabling disorder associated with myofascial and trigger point disorders in the neck. Pharmacological management is the first line of treatment; however, rehabilitation procedures aimed at lessening symptoms of myofascial and trigger point disorders may add value in the management of headache symptoms. AIM: To evaluate the feasibility of myofascial and trigger point treatment in chronic migraine patients receiving prophylactic treatment with onabotulinumtoxinA...
July 27, 2017: European Journal of Physical and Rehabilitation Medicine
keyword
keyword
3072
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"